Don’t miss the final two days of the ATS Keynote Series on Tuesday and Wednesday as speakers explore evidence for value-based care in pulmonary medicine, look at enhancing diversity and inclusion in academic medicine, and outline what pulmonologists should know about artificial intelligence and machine learning.

Keynotes are presented at 8 a.m. each day, when no other programming is scheduled, and highlight state-of-the-art lectures on a variety of topics to showcase major discoveries in pulmonary, critical care, and sleep medicine.

Robert M. Califf

Tuesday
Developing the Evidence for Value-Based Care in Pulmonary Medicine (K5)
Ballroom C One-Two (Level 2), KBHCCD

Robert M. Califf, MD, professor of cardiology and professor of medicine at Duke University School of Medicine in Durham, North Carolina, will explore ways real-world data can serve as evidence for value-based care.

Dr. Califf is a former commissioner of the Food and Drug Administration and former deputy commissioner for Medical Products and Tobacco. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, health care quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.

David S. Wilkes

Enhancing Diversity and Inclusion in Academic Medicine (K6)
Ballroom C Three-Four (Level 2), KBHCCD

David S. Wilkes, MD, dean of the School of Medicine at the University of Virginia in Charlottesville, will describe the value of an inclusive environment in the setting of academic medicine and outline the steps it will take to get there.

Dr. Wilkes is a nationally recognized physician-scientist who has served as a permanent member of study sections at the National Institutes of Health, as well as a member of the National Advisory Council for the National Institutes of Allergy and Infectious Diseases. Dr. Wilkes is a member of the Board of Scientific Counselors for the National Heart, Lung, and Blood Institute at NIH. Discoveries from Dr. Wilkes’ lab were the basis for his founding ImmuneWorks, a biotech company developing novel therapeutics for immune-mediated lung diseases.

Wednesday
What Should Pulmonologists Know About Artificial Intelligence and Machine Learning? (K7)
Ballroom C One-Two (Level 2), KBHCCD

Michael D. Howell

Michael D. Howell, MD, MPH, the chief clinical strategist for health care in Google Brain, will present key techniques in modern machine learning and how these differ from traditional statistical and programming approaches. He will also describe how to recognize important opportunities for artificial intelligence and machine learning to influence pulmonary medicine.

Dr. Howell was the founding director of the Center for Healthcare Delivery Science and Innovation and chief quality officer at the University of Chicago Medicine. His research has focused on novel uses of electronically derived health care data to create insights that improve patient care, with particular attention to patient safety, health care quality and operations, and diseases of the acutely ill such as sepsis, pneumonia, health care associated infections, and cardiac arrest.